For & Against
What's Next
Next earnings: May 11, 2026 (after close). Consensus calls for Q1 FY26 revenue of ~$621M (+6% YoY) and EPS of ~$0.06 — roughly a 70% YoY decline from Q1 FY25's $0.20, the first full quarter absorbing the branded Wegovy pivot. That single print is the pivot point: it is the first clean window into whether the margin compression the bull calls "stabilizing" and the bear calls "collapsing" actually shows up in the numbers.
The Street is already positioned below spot — mean 12-month target $24 despite a 37% one-month rally — and BofA (the most recent update, April 16) raised only to $25 with a neutral rating, citing ~50% YoY EBITDA compression from the Wegovy shift. What the market watches most closely on May 11 is not revenue (estimates are tight around $621M) but the gross margin and Adj EBITDA walk that tells you how much of the 800bps FY25 gross-margin drop is one-time vs structural.
For / Against / My View
Bull and Bear have already written the two sides of this name in full rigor. What follows is selection, not re-drafting — the sharpest three points from each, the places they actually disagree on the same number, and where the weight of evidence lands.
For
The base business is already a $1.5B+ profitable engine. Strip compounded GLP-1 out entirely and HIMS is still the only public DTC telehealth operator with positive GAAP net income, 74% gross margin, and 6–7 month marketing payback stable for four straight years — a profile the $6.4B market cap does not pay for.
Evidence: FY25 OCF of $300M (2.3x GAAP net income), ROE 23.7%, ROIC 13.9% on the enlarged capital base; marketing fell from 51% of revenue in FY23 to 39% in FY25 while absorbing a Super Bowl ad. Peer table confirms no other public telehealth name (TDOC, LFMD, AMWL, WW) combines positive growth and positive operating margin.
Personalization is the durable moat, and it is still compounding. Monthly ARPU jumped 28% to $83 in FY25 on only 13% subscriber growth because personalized SKUs crossed 70% of US revenue — multi-drug, non-generic, platform-exclusive formulations with pricing power independent of GLP-1 and independent of any DOJ/FDA compounded-semaglutide outcome.
Evidence: personalized crossed 70% of US revenue in FY25 vs ~50% in FY24; $2.35B FY25 revenue up 59%, Q4 still growing 28% YoY on a base already at scale; personalized offerings monetize at $81 vs $51 in FY21 — a structural revenue-per-user step-change that compounds even if net-adds slow.
Eucalyptus is a $450M international platform the sell-side is not modeling. The $1.15B deal closes mid-2026 and delivers Australia, Japan, UK, Germany, and Canada in a single stroke — plus a regulatory diversifier away from the US FDA compounded-drug fight, funded out of the $929M on the balance sheet.
Evidence: $240M cash at close, up to $1.15B total, against $929M of cash-and-investments and $973M convertibles at 0.25% coupon. International moved from intensity 0 to 5 in management emphasis while it remains absent from consensus forecasts.
Bull 12–15 month target
Primary catalyst: Q2 FY26 print showing gross margin stabilizing at 72%+ while Eucalyptus closes and begins contributing to FY27 run-rate — supports a re-rating to 3.5x forward revenue / 30x FY27 EBITDA. Disconfirming signal: paid-marketing payback extends beyond 9 months (historically 6–7 months for four years).
Against
FY26 guide is the thesis. Management's initial FY26 Adj. EBITDA guide of $300–375M (midpoint $337.5M) is only 6% above FY25 actual of $318M despite implied ~18% revenue growth — the margin line goes down, not up. It is the first guide in the public-company era where EBITDA steps on the accelerator of the P&L, landing on top of a 71% FCF collapse (FY24 $198M → FY25 $57M).
Evidence: "FY2026 Adj EBITDA guide midpoint $337.5M — BELOW FY25 $318M"; FY25 FCF $57M on $318M Adj EBITDA — 18% conversion, capex $243M; Adj EBITDA margin FY25 14%, FY24 12% — operating leverage flattening.
The GLP-1 pivot trades a proprietary SKU for a pass-through. Compounded semaglutide at $199/month was HIMS's highest-margin product — proprietary formulation, 85%+ contribution. The March 2026 pivot to distributing branded Wegovy at $599/month is a different economic transaction: Novo keeps the manufacturing margin, HIMS takes a distribution fee. Gross margin already fell 800bps (82% → 74%) in FY25 before branded mix hits.
Evidence: "$49 compounded pill withdrawn under FDA pressure Feb 2026; branded Wegovy at $599/mo via Novo — 12× price point, distribution not manufacture"; FY25 gross margin 74% vs 82%; "branded Wegovy distribution carries structurally lower margin than compounded."
Insiders are monetizing every rally; nobody is buying. $43.2M of open-market insider sales in 13 months, zero open-market purchases. CFO Okupe $20.6M, CEO Dudum $15.3M — concentrated at $50–63 in Sept/Oct 2025. The CFO has kept selling into the April 2026 rebound, ~78,500 shares between Apr 6 and Apr 22 at $20–30. In a controlled company where Dudum wields 88% of the votes against 7% of the economics, brokerage activity is the only reliable signal — and it is one-directional.
Evidence: "$43.2M insider sales 13 months, zero buys"; "CFO Okupe 78,500 shares sold Apr 6–22 2026 at $20–30 under 10b5-1; CLO also sold 9,463 @ $30 Apr 22"; "Dudum 88.17% voting / 7.42% economic via Class V super-voting (175 votes/share)."
Bear 12 month target
Primary trigger: Q1 or Q2 FY26 gross margin prints under 72% and/or Adj EBITDA margin under 11% — confirming the Wegovy pivot is margin-dilutive and forcing a cut to the FY26 midpoint guide. Covering signal: Q2 FY26 reclaims 74%+ gross margin with Adj EBITDA run-rate above $350M and subscriber growth re-accelerates past 20%.
The Tensions
1. Gross margin — residual shock or the leading edge of permanent compression?
Bull reads the FY25 74% gross margin as the trough of a one-year compounded-semaglutide mix shift with personalized SKUs (70% of US revenue, 85%+ contribution) preserving structural pricing power. Bear reads the exact same 74% as the leading edge of permanent compression — 800bps already gone before branded Wegovy hits the P&L, and Wegovy at $599 is a distribution fee, not a manufactured margin. Both cite FY25 gross margin of 74%, down from 82%. This resolves on the Q1 FY26 print on May 11 and, more definitively, Q2 FY26 in August: a print at 72%+ supports the bull; under 72% confirms the bear.
2. Cash — is $300M OCF or $57M FCF the right number?
Bull cites FY25 operating cash flow of $300M (2.3x GAAP net income) as proof HIMS has become a cash machine that can self-fund Eucalyptus out of the $929M on the balance sheet. Bear cites FY25 free cash flow of $57M (down 71% from $198M) on $243M of capex as proof the cash model is already broken — EBITDA-to-FCF conversion at 18%. Both cite the same FY25 cash statement. This resolves on the FY26 capex disclosure (first revealed on the May 11 print) and the FY26 FCF trajectory: capex normalizing toward $75–100M and FCF recovering above $150M vindicates the bull; capex staying above $200M while FCF remains under $75M confirms the bear.
3. CFO Okupe's April 6–22 sales — legacy 10b5-1 plan or live monetization?
Bull reads the ~78,500-share tranche at $20–30 as metronomic 10b5-1 execution of a plan filed when the stock sat at $50–60 — pre-dated, uninformed, not a new signal. Bear reads the same tranche as the latest chapter of an unbroken 13-month pattern ($43.2M out, zero buys), with the CFO selling into a 37% one-month rebound at prices 60% below his original sell zone. Both cite the same April 6–22 CFO Form 4s. This resolves on whether Okupe files a new 10b5-1 after the May 11 print (and at what price), and whether Dudum opens any open-market purchases within the next trading window — a new plan at current prices supports the bull; continued Okupe selling with silence from Dudum confirms the bear.
My View
Close call, but the slight edge goes to the cautious side. The For case rests on forward assertions — Eucalyptus scaling, a peptide revenue stream conditional on the July PCAC, non-GLP-1 compounding at 30%+ in isolation — while the Against case rests on numbers that are already in the print: a FY26 guide where EBITDA grows slower than revenue, FCF at 18% of EBITDA, 800bps of gross-margin compression before branded Wegovy hits, and 13 months of one-directional insider activity. Tension #1 tips it — the Q1 FY26 gross-margin print on May 11 is the first unambiguous piece of evidence either side has been arguing about, and it lands before any of the bull's positive catalysts (Eucalyptus close, July PCAC, Q2 re-acceleration). I'd wait for that number. A 72%+ gross margin with Adj EBITDA on a $350M+ run-rate — the bear's own covering signal — flips this view and reframes the Wegovy transition as margin-neutral rather than margin-destructive.